272 related articles for article (PubMed ID: 26935421)
1. Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.
Kadariya Y; Menges CW; Talarchek J; Cai KQ; Klein-Szanto AJ; Pietrofesa RA; Christofidou-Solomidou M; Cheung M; Mossman BT; Shukla A; Testa JR
Cancer Prev Res (Phila); 2016 May; 9(5):406-414. PubMed ID: 26935421
[TBL] [Abstract][Full Text] [Related]
2. Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.
Kadariya Y; Sementino E; Shrestha U; Gorman G; White JM; Ross EA; Clapper ML; Neamati N; Miller MS; Testa JR
Carcinogenesis; 2022 Dec; 43(12):1137-1148. PubMed ID: 36355620
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma.
Chow MT; Tschopp J; Möller A; Smyth MJ
Immunol Cell Biol; 2012 Nov; 90(10):983-6. PubMed ID: 23010873
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
[TBL] [Abstract][Full Text] [Related]
5. Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma.
Westbom C; Thompson JK; Leggett A; MacPherson M; Beuschel S; Pass H; Vacek P; Shukla A
PLoS One; 2015; 10(12):e0145404. PubMed ID: 26689911
[TBL] [Abstract][Full Text] [Related]
6. Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.
Comar M; Zanotta N; Zanconati F; Cortale M; Bonotti A; Cristaudo A; Bovenzi M
Lung Cancer; 2016 Apr; 94():61-7. PubMed ID: 26973208
[TBL] [Abstract][Full Text] [Related]
7. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
Sneddon S; Patch AM; Dick IM; Kazakoff S; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
BMC Cancer; 2017 Jun; 17(1):396. PubMed ID: 28577549
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
9. A mouse model recapitulating molecular features of human mesothelioma.
Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
[TBL] [Abstract][Full Text] [Related]
10. Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism.
Deswaerte V; Nguyen P; West A; Browning AF; Yu L; Ruwanpura SM; Balic J; Livis T; Girard C; Preaudet A; Oshima H; Fung KY; Tye H; Najdovska M; Ernst M; Oshima M; Gabay C; Putoczki T; Jenkins BJ
Cancer Res; 2018 Mar; 78(5):1293-1307. PubMed ID: 29282220
[TBL] [Abstract][Full Text] [Related]
11. Dose-response modeling of NLRP3 inflammasome-mediated diseases: asbestos, lung cancer, and malignant mesothelioma as examples.
Cox LA
Crit Rev Toxicol; 2019 Aug; 49(7):614-635. PubMed ID: 31905042
[TBL] [Abstract][Full Text] [Related]
12. Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.
Robinson C; Alfonso H; Woo S; Olsen N; Bill Musk AW; Robinson BW; Nowak AK; Lake RA
Lung Cancer; 2014 Oct; 86(1):29-34. PubMed ID: 25175318
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Carbone M; Yang H
Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079
[TBL] [Abstract][Full Text] [Related]
14. CREB-induced inflammation is important for malignant mesothelioma growth.
Westbom CM; Shukla A; MacPherson MB; Yasewicz EC; Miller JM; Beuschel SL; Steele C; Pass HI; Vacek PM; Shukla A
Am J Pathol; 2014 Oct; 184(10):2816-27. PubMed ID: 25111229
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.
Kumagai-Takei N; Yamamoto S; Lee S; Maeda M; Masuzzaki H; Sada N; Yu M; Yoshitome K; Nishimura Y; Otsuki T
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29419731
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
[TBL] [Abstract][Full Text] [Related]
17. Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention.
Toyokuni S
Free Radic Biol Med; 2019 Mar; 133():206-215. PubMed ID: 30312759
[TBL] [Abstract][Full Text] [Related]
18. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
Lecomte C; Andujar P; Renier A; Kheuang L; Abramowski V; Mellottee L; Fleury-Feith J; Zucman-Rossi J; Giovannini M; Jaurand MC
Cell Cycle; 2005 Dec; 4(12):1862-9. PubMed ID: 16319530
[TBL] [Abstract][Full Text] [Related]
19. Iron overload signature in chrysotile-induced malignant mesothelioma.
Jiang L; Akatsuka S; Nagai H; Chew SH; Ohara H; Okazaki Y; Yamashita Y; Yoshikawa Y; Yasui H; Ikuta K; Sasaki K; Kohgo Y; Hirano S; Shinohara Y; Kohyama N; Takahashi T; Toyokuni S
J Pathol; 2012 Nov; 228(3):366-77. PubMed ID: 22864872
[TBL] [Abstract][Full Text] [Related]
20. Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
Kinoshita Y; Takasu K; Yuri T; Yoshizawa K; Uehara N; Kimura A; Miki H; Tsubura A; Shikata N
Ann Diagn Pathol; 2013 Feb; 17(1):99-103. PubMed ID: 22784439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
